Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177194 | 0.88 | DRD2 (0.59) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL21760177 | 0.84 | ADRA2A (0.44) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL30487745 | 0.84 | ADRA2A (0.44) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL1091532 | 0.76 | MAPT (0.54) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL379224 | 0.76 | CA9 (0.57) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL532839 | 0.76 | DRD2 (0.78) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL1556861 | 0.76 | MAPT (0.54) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL531817 | 0.76 | MAPT (0.54) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL29722558 | 0.76 | DRD2 (0.78) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL5539388 | 0.76 | MAPT (0.54) | MAPTKDM4ECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686199-B9 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) | 2022-12-07 | — | — | EP | disclosed |
| US-11401256-B2 | Dihydroquinolinones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3611174-B1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2022-06-08 | — | — | EP | disclosed |
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-3686199-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2020-07-29 | — | — | EP | disclosed |
| EP-3611174-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | Medshine Discovery Inc. (CN) | 2020-02-19 | — | — | EP | disclosed |
| WO-2019183364-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2018039467-A1 | INHIBITORS OF-BCR-ABL MUTANTS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-01 | — | — | WO | disclosed |
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | MAPT 4146/4885KDM4E 1701/4885CA12 4777/4885 |
| US-11401256-B2 | Dihydroquinolinones for medical treatment | CRBN, RBX1, ADRM1 | MAPT 2439/4885KDM4E 1168/4885CA12 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.